Mankind Pharma Limited Receives Order from Office of Commissioner of Central Tax, Central Excise and Service Tax, Secunderabad GST Commissionerate GST Bhawan, Hyderabad
April 26, 2024 at 07:05 pm IST
Share
Mankind Pharma Limited announced that the Company has received an Order from Office of Commissioner of Central Tax, Central Excise and Service tax, Secunderabad GST Commissionerate GST Bhawan, Hyderabad ("Department") dated April 25, 2024 received on April 26, 2024 imposing a penalty of INR 2,452,328/- under applicable provisions of the CGST Act, 2017. The Company is examining the aforesaid Order received from the Department and shall take appropriate steps, including filing of an appeal. There is no material impact on financials, operations or other activities of the Company.
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The Company offers exceptional healthcare solutions for a wide range of healthcare needs with a diverse portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system (CNS), vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. The Company's subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Broadway Hospitality Services Private Limited, Jaspack Industries Private Limited, and others.
Mankind Pharma Limited Receives Order from Office of Commissioner of Central Tax, Central Excise and Service Tax, Secunderabad GST Commissionerate GST Bhawan, Hyderabad